Cannabis

Latest News

September 29th 2026

How Prevalent Is Simultaneous Alcohol-Cannabis Use?

Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.

August 31st 2026

How Do Cannabis Edibles Affect Driving? New Research Insights

By Leah Kuntz

August 20th 2026

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

By Leah Kuntz

July 16th 2026

Oral Cannabinoid From MediPharm Shows Significant Reduction in Agitation in Alzheimer Disease and Dementia

By Jessica Walters

July 16th 2026

The Psychiatric Impact of Cannabis Policy: More Than a Legal Framework

By Mira Zaboube, BS, Nidal Moukaddam, MD, PhD

Latest Videos

Addressing the Treatment Gap in Cannabis Use Disorder

Treating Cannabis Use Disorder & Withdrawal With PP-01: NIDA Grant Accelerates Phase 3 Trial

Developments in Cannabis Withdrawal and Addiction Treatment

Treating Cannabis Addiction and Withdrawal: Latest Clinical Data

Shorts

1:11

Treatment for Cannabis Use Disorder With PP-01

12 days ago

by

Shelli Graham, PhD

CME Content

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

More News

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

ByMichael Murphy, MD, PhD,Allison Nelson-Eliot, LICSW

June 18th 2026

Key steps for first-episode psychosis: team-based care, low-dose meds, relapse planning, family support, and cannabis harm reduction.

Cannabis and Psychosis Risk: How Legalization Could Impact Clinical Practice

ByFawad Taj, MD

May 5th 2026

New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.

Cannabis

Latest News

Latest Videos

Addressing the Treatment Gap in Cannabis Use Disorder

Treating Cannabis Use Disorder & Withdrawal With PP-01: NIDA Grant Accelerates Phase 3 Trial

Developments in Cannabis Withdrawal and Addiction Treatment

Treating Cannabis Addiction and Withdrawal: Latest Clinical Data

Shorts

CME Content

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

More News

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

Cannabis and Psychosis Risk: How Legalization Could Impact Clinical Practice

Trending on Psychiatric Times

What Clinicians Need to Know About Postpartum Psychosis

Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD

ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials

Nature vs Nurture: The Interplay Between Genetics and Environmental Influences

Esketamine, Off-Label Ketamine, and the Regulatory Gap: A Conversation With Lisa Harding, MD